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Abstract
Background: Acute kidney injury (AKI) is a frequently occurring syndrome in critically ill patients and is associated
with worse outcomes. Biomarkers allow early identification and therapy of AKI which may improve outcomes. Urine
chitinase 3-like protein 1 (uCHI3L1) was recently identified as a promising urinary biomarker for AKI. In this multicenter
study, we evaluated the diagnostic performance for AKI stage 2 or greater of uCHI3L1 in comparison with the urinary
cell cycle arrest biomarkers urinary tissue inhibitor of metalloproteinases-2 (TIMP-2)•insulin-like growth factor-binding
protein 7 (IGFBP7) measured by NephroCheck Risk®.
Methods: Post hoc laboratory study of the prospective observational FINNAKI study. Of this cohort, we included
patients with stored admission urine samples and availability of serum creatinine at day 1 of admission. Patients who
already had AKI stage 2 or 3 at ICU admission were excluded. AKI was defined and staged according to the KDIGO
definition and staging system. The primary endpoint was AKI stage 2 or 3 at day 1. Biomarker performance was
assessed by the area under the curve of the receiver operating characteristic curve (AUC). We assessed individual
performance and different combinations of urine biomarkers.
Results: Of 660 included patients, 49 (7.4%) had AKI stages 2–3 at day 1. All urine biomarkers were increased
at admission in AKI patients. All biomarkers and most combinations had AUCs < 0.700. The combination
uCHI3L1•TIMP-2 was best with a fair AUC of 0.706 (0.670, 0.718). uCHI3L1 had a positive likelihood ratio (LR)
of 2.25 which was comparable to that of the NephroCheck Risk® cutoff of 2.0, while the negative LR of 0.53
was comparable to that of the NephroCheck Risk® cutoff of 0.3.
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Conclusions: We found that uCHI3L1 and NephroCheck Risk® had a comparable diagnostic performance for diagnosis
of AKI stage 2 or greater within a 24-h period in this multicenter FINNAKI cohort. In contrast to initial discovery and
validation studies, the diagnostic performance was poor. Possible explanations for this observation are differences in
patient populations, proportion of emergency admissions, proportion of functional AKI, rate of developing AKI, and
observation periods for diagnosis of AKI.
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Background
Acute kidney injury (AKI) is a commonly occurring syn-
drome in critically ill patients admitted to the intensive
care unit (ICU) and is associated with increased morbidity
and mortality [1]. Recent studies indicate that the inci-
dence of AKI in ICU patients varies between 39 and 56%
when defined by the Kidney Disease: Improving Global
Outcomes (KDIGO) consensus criteria [2–4]. These cri-
teria define AKI based upon an increase of plasma creatin-
ine concentration (Cr) or a period of decreased urine
output (UO), and so reflect changes in glomerular filtra-
tion rate (GFR). Kidney biomarkers indicate stress or
damage to the kidney tubular cells, thus giving additional
information potentially at an earlier stage than Cr or UO
[5]. This may be of importance since more early identifica-
tion and stratification of therapy by the use of AKI bio-
markers can improve outcomes [6, 7].
At present, the 2-biomarker panel of the cell cycle arrest
biomarkers urinary tissue inhibitor of metalloproteinases-
2 (TIMP-2)•insulin-like growth factor-binding protein 7
(IGFBP7) has shown the best predictive value for AKI in
general ICU patients [5]. Given, the heterogeneous eti-
ology of AKI and also different patients’ baseline charac-
teristics, different biomarkers may be complimentary to
each other. Recently, we showed in a single-center pro-
spective cohort study that urinary chitinase 3-like protein
1 (uCHI3L1) is a promising AKI biomarker in ICU pa-
tients when compared to urinary neutrophil gelatinase-
associated lipocalin (uNGAL) [8]. A subsequent study by
our group in adult patients who underwent elective car-
diac surgery demonstrated that in this specific setting,
both uCHI3L1 and uNGAL showed inadequate predictive
value for AKI [9].
The aim of this study was to evaluate uCHI3L1 as a bio-
marker for AKI in ICU patients included in the multicenter
Finnish Acute Kidney Injury (FINNAKI) study and compare
this to the NephroCheck Risk® score, the composite of the
cell cycle arrest biomarkers TIMP-2 and IGFBP7. This may
provide external validation to the biomarker uCHI3L1 that
showed promise in our single-center study [8].
Methods
This was a post hoc laboratory study of the prospective,
observational FINNAKI study conducted in 17 Finnish
intensive care units (ICUs) between September 1, 2011,
and February 1, 2012 [4]. The Ethics Committee of the
Department of Surgery at the Helsinki University Hos-
pital gave a nationwide approval for the study. To in-
clude patients, we used deferred consent and as soon as
possible obtained a written, informed consent. Each pa-
tient or his/her next of kin gave a written, informed con-
sent. The study was conducted according to the
Declaration of Helsinki. Reporting is according to the
STROBE guidelines (suppl. data) [10].
Patients
We enrolled all patients with an emergency admission to
the ICU of any duration or an elective post-surgical ad-
mission expected to last over 24 h in the primary study
[4]. Patients were excluded if they (1) had end-stage
renal disease requiring maintenance dialysis; (2) were
organ donors; (3) received intermediate care, since our
focus was on critically ill patients; (4) had received renal
replacement therapy (RRT) while enrolled in the study
during previous ICU admission; (5) were transferred
from another ICU where the data collection for the
study was fulfilled; or (6) were not permanently living in
Finland or were unable to give consent due to insuffi-
cient language skills as informed consent needs to be
given using mother tongue. From the current analysis,
we further excluded patients who (1) were enrolled to
the study before December 1, 2011, and did not have
centrifuged urine samples; (2) did not consent for urine
sampling or where no sample was taken; (3) had under-
gone surgery with cardiopulmonary bypass; these were
excluded as uCHI3L1 proved of less value in this cohort
in a previous study; (4) had already stage 2 or 3 AKI
within 2 h of ICU admission; (5) were treated with RRT
for non-renal indications, as this would lead to false pos-
itives when non-renal use of RRT is classified as AKI; or
(6) did not have a blood sample taken at 24 h from ad-
mission and also no routine Cr measurement taken 12
to 25 h from admission. If one of these samples was
present, the patient was included (Fig. 1).
Sample collection
Urine samples were collected within 2 h once the patient
was admitted to the ICU. Additionally, blood and urine
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were collected 24 h later if the patient was still in the
ICU. Urine samples were centrifuged and frozen in ali-
quots. Kidney biomarkers were analyzed on urine sam-
ples that were collected within 2 h. Blood samples were
collected in EDTA tubes and centrifuged, aliquoted, and
frozen. Samples were kept in − 80° until analyzed.
Laboratory assays
The uCHI3L1, urinary TIMP-2, urinary IGFBP7, and
NephroCheck Risk® analyses were performed in 2018. The
laboratory analyses were performed blinded to the clinical
data and the KDIGO classification. We measured the con-
centration of uCHI3L1 by a sandwich enzyme-linked im-
munosorbent assay (ELISA) technique (DC3L10, R&D
Systems, Minneapolis, MN, USA). With the Astute140®
Meter, we measured the concentrations of urinary TIMP-
2, urinary IGFBP7, and NephroCheck Risk® by a fluores-
cent immunoassay technique (NephroCheck® Test, Astute
Medical, San Diego, CA, USA). Details on these laboratory
analyses were recently described [9].
In addition, we also evaluated the combinations of
uCHI3L1 and the individual cell cycle arrest biomarkers
and the NephroCheck Risk® for the prediction of AKI
stage 2 or greater. Similar to the NephroCheck Risk®, this
was done by multiplying the concentrations of individual
biomarkers, e.g., uCHI3L1 conc x TIMP-2 concentration.
Data collection
We collected data on patients’ baseline characteristics
and risk factors for AKI with case report forms. These
data were supplemented by physiological and laboratory
data, disease severity scores, and ICU diagnoses from the
ICU data management system via the Finnish Intensive
Care Consortium database. The attending clinicians
screened the patients for the presence of sepsis accord-
ing to the ACCP/SCCM definition until day 5 [11]. The
presence of pre-existing chronic kidney disease (CKD)
was defined as GFR < 60 mL/min/1.73m2 as mentioned
in patients’ medical records.
Diagnosis of AKI and study endpoints
In the FINNAKI study, we classified AKI according to
the KDIGO definition on routinely measured Cr and
hourly UO as well as RRT in the ICU. As baseline Cr,
we used the most recent value obtained within a year
but at least a week preceding ICU admission. If baseline
Cr was not available and patients had no previous his-
tory of CKD, a Modification of Diet in Renal Disease
(MDRD) equation-derived baseline creatinine was used,
assuming a minimum GFR of 75 mL/min/1.73m2 follow-
ing the Acute Dialysis Quality Initiative (ADQI) and
KDIGO recommendations [2, 12]. The study protocol
did not include scheduled Cr measurements, and all data
were observational. Cr was generally measured once
daily in the morning lab tests. For the purpose of the
current analysis, we analyzed all available plasma sam-
ples taken at 24 h for Cr (n = 588 patients). Additionally,
72 patients had Cr measured as part of the ICU lab rou-
tines within 12 to 25 h from ICU admission. Thus, an
index Cr measured at least 12 h but not more than 25 h
Fig. 1 Patients’ flow chart
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from admission was available from 660 patients. All
these patients also had urine output recordings at least
for 12 h and data about RRT use in the ICU. Based on
these data, we formed the primary endpoint of the ana-
lysis: AKI stage 2 or 3 at 24 h.
As a sensitivity analysis, we analyzed the biomarker
performance to predict (1) AKI of any severity at 24 h,
(2) AKI of any severity at 48 h, and (3) stage 2 or 3 AKI
at 48 h. The latest Cr values and UO recordings available
up to 48 h from ICU admission were used to define the
patient’s AKI status at 48 h. Longer time periods were
not considered, since multiple events may contribute to
the occurrence of AKI. If these occur after the measure-
ment of the biomarker, there will be a negative bio-
marker reading. These patients will so incorrectly be
classified as false negatives: negative biomarker and still
occurrence of AKI.
Statistical analysis
We report the non-normally distributed continuous
data as median with interquartile range (IQR) and
categorical data with count and percentage. We com-
pared continuous data using Mann-Whitney U test
and categorical data with Fisher’s exact test or chi-
square test where appropriate. We assessed the pre-
dictive ability of the biomarkers and combinations for
the primary endpoint by calculating the area under
the receiver-operator characteristic curve (AUC-ROC)
and compared these according to the method of
DeLong et al. and with the calculation of binomial
exact 95% confidence intervals [13]. For uCHI3L1 and
the combination of this biomarker with the other bio-
markers, we assessed a cutoff based on the Youden
index [14]. We considered a two-sided p value less
than 0.05 as significant and did not correct for mul-
tiple comparisons.
We pre-defined the AUC as follows: excellent, 0.900 ≤
AUC-ROC ≤ 1; good, 0.800 ≤AUC-ROC ≤ 0.899; fair,
0.700 ≤AUC-ROC ≤ 0.799; poor, 0.600 ≤AUC-ROC ≤
0.699; and failed when AUC-ROC < 0.600 [15].
Analyses were conducted using SPSS Statistics 23.0 for
Microsoft and 24.0 for Mac (IBM, Armonk, NY), MedCalc
Statistical Software version 19.0.4 (MedCalc Software
bvba, Ostend, Belgium), and RStudio 1.1.456 for Mac.
Results
A total of 660 patients were included in this study
(Fig. 1). Of these, 120 (18.2%) patients had AKI at
time 24 h after ICU admission. Their baseline charac-
teristics are provided in Table 1. Of these patients,
96% were emergency admissions, 70% received mech-
anical ventilation, and 54.2% of them were adminis-
tered norepinephrine. Altogether, 21 patients (3.2%)
had AKI stage 1 diagnosed within 2 h of ICU
admission. Of these, 5 patients had AKI stage 2 or 3
at 24 h and 4 at 48 h.
KDIGO AKI stage 2–3 criteria were met by 49 patients
(7.4%) at 24 h (i.e., the primary endpoint). Of those 49,
AKI criteria were met by 27 (55.1%) using Cr criteria
and in 29 (59.1%) using UO criteria; 10 patients (20.4%)
were treated with RRT within the first 24 h after ICU ad-
mission. AKI was diagnosed by Cr criteria only in 15 pa-
tients (30.6%) and UO criteria only in 17 patients
(34.7%), 12 patients (24.5%) met both Cr and UO cri-
teria, and in 5 patients, AKI was diagnosed on use of
RRT only.
Patients with AKI stage 2 or greater were older and
had higher baseline creatinine compared to patients with
AKI stages 0–1. AKI stage 2–3 patients had more risk
factors for AKI such as hypovolemia, massive transfu-
sion, acute liver failure, cardiogenic shock, administra-
tion of hydroxyethyl starch or peptidoglycan antibiotics,
and emergency or surgical admission. Finally, AKI stage
2–3 patients had higher SAPS II and SOFA scores and
received more often mechanical ventilation and/or
norepinephrine.
Urinary biomarkers for early diagnosis of AKI stage 2 or 3
at 24 h
Patients with AKI stage 2 or greater at 24 h had higher
concentrations for all urinary biomarkers and for the dif-
ferent combinations thereof measured at ICU admission
(Table 2).
The AUC-ROCs for AKI stage 2 or greater at 24 h
were poor (< 0.700) for all biomarkers and their combi-
nations, except for the combination uCHI3L1•TIMP-2
with a fair AUC-ROC of 0.706 (Fig. 2). This AUC-ROC
was not statistically significantly higher than those of ei-
ther uCHI3L1 or NephroCheck Risk® alone.
Based on a Youden analysis, the best cutoff for
uCHI3L1 was assessed, and these sensitivity and specifi-
city values were found to be in between those of the
NephroCheck Risk® cutoff values of 0.3 and 2.0 (Table 3)
[16]. The positive likelihood ratio (LR) of AKI stage 2 or
greater for uCHI3L1 was comparable to that of the
NephroCheck Risk® 2.0 cutoff, while the negative LR was
comparable to that of the NephroCheck Risk® 0.3 cutoff
(Table 3). Combining uCHI3L1 either with IGFBP7 or
with the NephroCheck Risk® resulted in an increase of
the specificity, a decrease of sensitivity, and the highest
positive LRs.
Sensitivity analyses
The AUC-ROCs for AKI of any severity of AKI at 24 h for
all biomarkers and their combinations were poor (< 0.700).
Sensitivity, specificity, and positive and negative likelihood ra-
tios were corresponding to that of the primary endpoint
(Additional file table 1). The results regarding AKI of any
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severity at 48 h (Additional file Table 2) and stage 2 or 3 AKI
at 48 h (Additional file table 3) corroborated that of the pri-
mary endpoint.
Discussion
In this multicenter validation study, we found that
uCHI3L1 was markedly increased in general ICU pa-
tients who developed AKI stage 2 or 3 within a 24-h
Table 1 Baseline characteristics of patients
Data
available
All patients AKI stage 2 or 3 at 24 h
(n = 49)
AKI stage 0 or 1 at 24 h
(n = 611)
p value
Age (years) 660 64 [53–73] 68 [57–77] 64 [52–73] 0.038
Male sex 660 410/660 (62.1%) 35/49 (71.4%) 375/611 (61.4%) 0.172
BMI (kg/m2) 658 26.1 [23.4–29.4] 26.3 [24.4–30.9] 26.1 [23.4–29.4] 0.275
Baseline creatinine (μmol/L) 393 75 [61–95] 81 [68–107] 75 [60–93] 0.028
Baseline Cr with missing values imputed*
(μmol/L)
660 82 [69–95] 90 [74–99] 81 [69–95] 0.058
Diabetes mellitus 660 139/660 (21.2%) 11/49 (22.4%) 128/611 (20.9%) 0.855
Arteriosclerosis 650 90/650 (13.6%) 10/48 (20.8%) 80/602 (13.3%) 0.189
CKD 659 41/659 (6.2%) 4/49 (8.2%) 37/610 (6.1%) 0.535
Chronic liver disease 654 20/654 (3.0%) 1/49 (2.0%) 19/605 (3.1%) > 0.999
Hypertension 652 304/652 (46.1%) 24/49 (49.0%) 280/603 (46.4%) 0.767
Systolic heart failure 651 61/651 (9.2%) 6/48 (12.5%) 55/603 (9.1%) 0.438
Chronic obstructive pulmonary disease 656 73/656 (11.1%) 7/49 (14.3%) 66/607 (10.9%) 0.477
Pre-ICU AKI risk factors**
Sepsis 660 144/660 (21.8%) 14/49 (28.6%) 130/611 (21.3%) 0.279
Hypovolemia 657 179/657 (27.1%) 23/49 (46.9%) 156/608 (25.7%) 0.002
Cardiopulmonary resuscitation 660 86/660 (13.0%) 6/49 (12.2%) 80/611 (13.1%) > 0.999
Massive transfusion 660 16/660 (2.4%) 4/49 (8.2%) 12/611 (2.0%) 0.025
Acute liver failure 660 10/660 (1.5%) 3/49 (6.1%) 7/611 (1.1%) 0.032
Cardiogenic shock 660 19/660 (2.9%) 7/49 (14.3%) 12/611 (2.0%) < 0.001
Radiocontrast 657 189/657 (28.6%) 14/48 (29.2%) 175/609 (28.7%) > 0.999
Diuretics 639 190/639 (28.8%) 17/47 (36.25%) 173/592 (29.2%) 0.323
Angiotensin converting enzyme inhibitor
or angiotensin receptor blocker
645 145/645 (22.5%) 13/48 (27.1%) 132/597 (22.1%) 0.472
Non-steroidal anti-inflammatory drug 622 61/622 (9.8%) 5/45 (11.1%) 56/577 (9.7%) 0.793
Hydroxyethyl starch 645 78/645 (12.1%) 17/49 (34.7%) 61/596 (10.2%) < 0.001
Peptidoglycan antibiotic 659 28/659 (4.2%) 5/49 (10.2%) 23/610 (3.8%) 0.049
Emergency admission 660 635/660 (96.2%) 44/49 (89.8%) 591/611 (96.7%) 0.031
Surgical admission 660 191/660 (29.1%) 22/49 (44.9%) 170/611 (27.8%) 0.014
Admitted from
Operation room or recovery 660 177/660 (26.8%) 22/49 (44.9%) 155/611 (25.4%) 0.004
Emergency department 660 272/660 (41.2%) 8/49 (16.3%) 264/611 (43.2%) < 0.001
Ward 660 131/660 (19.8%) 15/49 (30.6%) 116/611 (19.0%) 0.062
Other ICU/high-dependency unit/others 660 80/660 (12.1%) 4/49 (8.2%) 76/611 (12.4%) 0.497
SAPS II (24 h) 660 38 [29–49] 52 [37–63] 37 [28–48] < 0.001
SOFA (24 h) 660 7 [4–9] 10 [8–13] 6 [4–9] < 0.001
Mechanical ventilation during ICU stay 660 462/660 (70.0%) 43/49 (87.8%) 419/611 (68.6%) 0.003
Norepinephrine (within 24 h) 660 358/660 (54.2%) 43/49 (87.8%) 315/611 (51.6%) < 0.001
*MDRD equation assuming GRF ≥ 75mL/min/1.73 m2. Imputed for 16 patients with endpoint+ and 251 with endpoint−
**Pre-ICU AKI risk factors if present in 48 h preceding ICU admission
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period after their ICU admission. Urine CHI3L1 had a
comparable diagnostic performance to TIMP-2•IGFBP7.
Combining uCHI3L1 with the NephroCheck Risk® or
IGFBP7 resulted in a less sensitive but a more specific test
with the highest positive LRs (i.e., 1.69 to 2.75). However,
LRs of this magnitude will generate a little effect on post-
test disease probability in clinical practice [15].
This study and previous studies on uCHI3L1 have
demonstrated its use as a biomarker for diagnosis of
AKI, and this with comparable performance to uNGAL
and NephroCheck Risk® [8, 9, 17–19]. CHI3L1 may also
provide mechanistic insights in injury and repair mecha-
nisms in the kidney. Kidney stress or damage will pro-
mote that macrophages in the kidney secrete CHI3L1
[17]. Biological effects of CHI3L1 include control of cell
death, inflammation, and remodeling in renal epithelial
cells and macrophages [20–22].
Notably, the diagnostic performance for AKI stage 2
or 3 within a 24-h period was markedly lower when
compared to earlier validation studies for uCHI3L1 and
NephroCheck Risk® [7, 8]. Indeed, we showed in a
single-center general ICU cohort that for diagnosing
AKI stage 2 or greater, uCHI3L1 had an AUC-ROC of
0.784 at 12 h and 0.721 at 24 h [8]. In the Sapphire
study, the NephroCheck Risk® which combines the two
biomarker urinary proteins TIMP-2 and IGFBP7 had an
AUC-ROC of 0.80 at 12 h [5]. How should the current
FINNAKI study data be interpreted? First, as AKI is a
syndrome with marked heterogeneity, it is very likely
that unmeasured confounders play a role in differences
in the diagnostic performance of kidney biomarkers.
While all 3 studies included patients from ICUs from
developed countries in an apparently similar setting and
with comparable age, comorbidities, and risk factors,
there may have been differences in the baseline charac-
teristics of patients. This hypothesis can be illustrated by
the differences in the occurrence of AKI stage 2 or
greater at 24 h. In the uCHI3L1 validation study, we
found that 5% of patients developed AKI stage 2 or
greater at 24 h compared to 7.4% in this study and to
14% within 12 h in the Sapphire study. A comparative
overview of the baseline characteristics of these three
studies (FINNAKI-CHI3L1 versus BAKI-I and Sapphire)
is provided in Table 4. Strikingly, age, diabetes, baseline
Cr, severity of illness, and type of ICU patients are dif-
ferent between studies. Apparently, a marked proportion
of patients already have developed AKI stage 2 or greater
when admitted to the ICU. Thus, potential interesting
endpoints for future biomarker research would be the
non-resolution of AKI. Second, the timing of diagnosis
may explain the differences in AUC. Here, we measured
AKI occurrence within a 24-h period after admission, a
period during which ICU patients typically experience a
complicated and eventful clinical course. Several new
events may occur during this period resulting in injury
or stress to the kidneys. A biomarker reading before
these events occur will inevitably underestimate or miss
this. Others have also reported lower AUCs for the
NephroCheck Risk® when a longer detection period was
used [23–25]. Third, the risk of progression to AKI stage
2 from baseline no AKI may be lower compared to base-
line AKI stage 1. Therefore, a large proportion of no
AKI patients at the time of inclusion may lower the
diagnostic performance compared to studies in which a
higher number of patients already had AKI stage 1 at in-
clusion. In our study, the majority of patients had no
AKI (96.2%) at the time of inclusion. In Sapphire and
BAKI-I, the number of patients who already had AKI
stage 1 at the time of inclusion was not reported. Fourth,
AKI is a syndrome with heterogeneous baseline charac-
teristics. However, we consider our study population and
findings representative to usual care in developed coun-
tries given the nationwide multicenter design, the inter-
nationally high standard of intensive care in Finland,
consecutive inclusion of all patients with a deferred con-
sent policy, a low rate of patients excluded without
Table 2 Biomarker levels. Median [IQR] biomarker concentrations in patients according to positive or negative primary endpoint
(KDIGO stage 2 or 3 AKI at 24 h)
AKI stage 2 or 3 at 24 h (n = 49) AKI stage 0 or 1 at 24 h (n = 611) p value
uCHI3L1 (ng/mL) 3.92 [0.12–12.45] 0.44 [0.12–2.42] < 0.001
TIMP-2 (ng/mL) 6.40 [3.15–10.15] 3.40 [1.80–6.10] < 0.001
IGFBP7 (ng/mL) 109.0 [46.9–300.9] 64.3 [32.4–128.9] 0.01
NephroCheck Risk® (ng/mL)2/1000 0.96 [0.19–2.64] 0.22 [0.06–0.85] < 0.001
NephroCheck Risk® > 0.3 and ≤ 2.0 (ng/mL)2/1000 22/49 (44.9%) 190/611 (31.1%) < 0.001
NephroCheck Risk® > 2.0 (ng/mL)2/1000 14/49 (28.6%) 75/611 (12.3%)
uCHI3L1•TIMP-2 (ng/mL)2 19.18 [1.34–113.50] 1.24 [0.27–13.95] < 0.001
uCHI3L1•IGFB7 (ng/mL)2 199.6 [19.4–2932.9] 20.9 [5.1–221.7] < 0.001
uCHI3L1•NephroCheck Risk® (ng/mL)3/1000 2.04 [0.11–28.13] 0.09 [0.01–1.31] < 0.001
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informed consent, and the exclusion of patients with
AKI already at ICU admission from this analysis [26].
Strengths and limitations
Our study has several strengths such as the multicenter
study design with a diagnosis of AKI according to the full
KDIGO definition and staging system in a large cohort of
ICU patients. As such, this is the first external validation
study of uCHI3L1 in general ICU patients compared with
the NephroCheck Risk®, the current best-performing AKI
biomarker for early diagnosis and kidney stress. Finally,
we also assessed the diagnostic performance of uCHI3L1
in combination with the NephroCheck Risk® test and its
individual elements. Therefore, we believe the results of
Fig. 2 ROC curves for biomarkers for the primary endpoint: AKI stage 2 or 3 at 24 h (n = 49 positive)
Table 3 Diagnostic performance of biomarkers and biomarker combinations for AKI defined by KDIGO occurring at 24 h
Biomarker Cutoff value Sensitivity Specificity Positive LR Negative LR
uCHI3L1 (ng/mL) > 2.1 61.2% (46.2, 74.8) 72.8% (69.1, 76.3) 2.25 (1.74, 2.92) 0.53 (0.37, 0.76)
NephroCheck Risk® (ng/mL)2/1000 > 0.3 73.5% (58.9, 85.1) 56.6% (52.6, 60.6) 1.69 (1.34, 2.05) 0.47 (0.29, 0.75)
NephroCheck Risk® (ng/mL)2/1000 > 2.0 28.6% (16.6, 43.3) 87.7% (84.9, 90.2) 2.33 (1.43, 3.80) 0.81 (0.68, 0.97)
uCHI3L1•TIMP-2 (ng/mL)2 > 5.5 65.3% (50.4, 78.3) 67.3% (63.4, 71.0) 2.00 (1.58, 2.52) 0.52 (0.35, 0.76)
uCHI3L1•IGFBP7 (ng/mL)2 > 459.8 46.9% (32.5, 61.7) 80.7% (77.3, 83.7) 2.43 (1.73, 3.41) 0.66 (0.50, 0.86)
uCH3L1• NephroCheck Risk® (ng/mL)3/1000 > 3.3 48.9% (34.4, 63.7) 82.2% (78.9, 85.1) 2.75 (1.97, 3.83) 0.62 (0.47, 0.82)
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this study are generalizable to patients admitted to ICUs
in developed countries in similar settings.
Our study has also some limitations to be considered.
First, we were able to include only 660 patients from the
full cohort (n = 2901), because only a proportion of the
full FINNAKI multicenter cohort had centrifuged frozen
urine samples available. However, we consider possible
bias as limited since these 660 patients represented the
last consecutively admitted patients of the study. Second,
plasma Cr was not sampled exactly at 24 h, but rather
within a 12- to 25-h time frame. Third, although un-
likely, we cannot exclude that pre-analytical issues may
have resulted in false-negative biomarker measurements.
For instance, despite deep-frozen storage at − 80 °C, the
7-year time delay between sample collection and analysis
may have caused some protein degradation resulting in
decreased detection of biomarkers. Fourth, patients with
AKI stage 2 or greater were more severely ill, had higher
baseline Cr, and more patients had pre-ICU risk factors.
CHI3L1, TIMP-2, and IGFBP7 are mediators that are
also elevated in the plasma in acute and chronic diseases
[27–34]. Johnson and Zager demonstrated that TIMP-2
and IGFBP7 are filtered by the glomeruli [35]. Given the
low molecular weight of 39–40 kDa, also CHI3L1 may
be filtered by the glomeruli. In summary, we cannot ex-
clude that systemic TIMP-2, IGFBP7, and CHI3L1 en-
tered the urine by glomerular filtration and so impacted
on the diagnostic performance. Fifth, serial measurement
of biomarkers could have provided deeper insights into
the biomarker signals.
Conclusions
We found that uCHI3L1 and NephroCheck Risk® had a
comparable diagnostic performance for diagnosis of AKI
stage 2 or greater within a 24-h period in this multicen-
ter FINNAKI cohort. In contrast to initial discovery and
validation studies, the diagnostic performance was poor.
Possible explanations for this observation were differ-
ences in patient populations, proportion of emergency
admissions, proportion of functional AKI, rate of devel-
oping AKI, and observation periods for diagnosis of AKI.
Our findings warrant additional multicenter validation
studies for these biomarkers using consecutive critically
ill patients and a scrutinized evaluation of additional
clinical value before their wider implementation in clin-
ical practice.
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